Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Cancer
Christine M HeskeLeo Mascarenhas

Abstract

The objective of this analysis was to evaluate the clinical factors influencing survival outcomes in patients with localized (clinical group I-III), FOXO1 fusion-positive rhabdomyosarcoma (RMS). Patients with confirmed FOXO1 fusion-positive RMS who were enrolled on 3 completed clinical trials for localized RMS were included in the analytic cohort. Outcomes were analyzed using the Kaplan-Meier method to estimate event-free survival (EFS) and overall survival (OS), and the curves were compared using the log-rank test. A Cox proportional hazards regression model was used to perform multivariate analysis of prognostic factors that were significant in the univariate analysis. The estimated 4-year EFS and OS of 269 patients with localized, FOXO1 fusion-positive RMS was 53% (95% CI, 47%-59%) and 69% (95% CI, 63%-74%), respectively. Univariate analysis revealed that several known favorable clinical characteristics, including age at diagnosis between 1 and 9 years, complete surgical resection, tumor size ≤5 cm, favorable tumor site, absence of lymph node involvement, confinement to the anatomic site of origin, and PAX7-FOXO1 fusion, were associated with improved outcomes. Multivariate analysis identified older age (≥10 years) and large ...Continue Reading

References

Jan 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W A NewtonH Maurer
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S PappoH E Grier
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K S BakerW M Crist
Sep 15, 2001·British Journal of Cancer·J AndersonUNKNOWN UK Children's Cancer Study Group (UKCCSG) and the UK Cancer Cytogenetics Group
May 17, 2005·Cancer·Stefano MazzoleniUNKNOWN Associazione Italiana di Ematologia e Oncologia Pediatrica Soft Tissue Sarcoma Committee
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jane L MezaUNKNOWN Children's Oncology Group
Jul 7, 2007·Fetal and Pediatric Pathology·Bernarda KazanowskaEwa Koscielniak
Jan 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tobias M DantonelloEwa Koscielniak
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elai DavicioniTimothy J Triche
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel WilliamsonOlivier Delattre
Sep 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leo MascarenhasDouglas S Hawkins
Mar 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julia C ChisholmOdile Oberlin
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edoardo MissiagliaJanet Shipley
Feb 19, 2013·Pediatric Blood & Cancer·Tobias M DantonelloUNKNOWN Cooperative Weichteilsarkom Studiengruppe
May 30, 2013·American Society of Clinical Oncology Educational Book·Erin R Rudzinski
Oct 12, 2013·Advances in Anatomic Pathology·David M Parham, Frederic G Barr
Jan 7, 2017·Expert Review of Molecular Diagnostics·Michael A Arnold, Fredric G Barr
Aug 10, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Douglas S HawkinsWilliam H Meyer
Dec 7, 2018·International Journal of Radiation Oncology, Biology, Physics·Dana L CaseySuzanne L Wolden
Dec 20, 2018·International Journal of Cancer. Journal International Du Cancer·Wenyue SunFrederic G Barr
Jan 9, 2019·Nature Reviews. Disease Primers·Stephen X SkapekDouglas S Hawkins
Sep 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leo MascarenhasDouglas S Hawkins

❮ Previous
Next ❯

Citations

Jun 29, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leo Mascarenhas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.